Following a nearly decade-long effort, Delcath Systems finally won the FDA’s greenlight for its Hepzato Kit for the liver-directed treatment of adult patients with metastatic uveal melanoma.
https://www.pharmalive.com/wp-content/uploads/2023/08/cancer-cells-liver.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-08-16 09:02:122023-08-16 09:24:40Delcath gets FDA approval for cancer drug-device combo 10 years after rejection
